This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Leerink Partnrs analysts have boosted Pfizer’s Q2 2025 earnings forecast from $0.52 to $0.57 per share, showing newfound ...

Some of the gains have come as the broader market has rallied, but there are signs fundamental factors are at play as well.

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

The global HIV antivirals market is experiencing a period of robust growth, driven by a combination of rising global awareness, remarkable advancements in pharmaceutical research, and the increasing ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...